Phase I study to assess tolerability, safety and PK of MGB-BP-3 in healthy volunteers

MGB生物制药公司正在开发一种新型抗生素，这种抗生素最初是由英国斯特拉斯克莱德大学的研究人员发现的。这种名为MGB-BP-3的药物具有一种新的作用机制，这意味着不会像现有抗生素那样出现耐药细菌。要开发的第一个适应症是治疗艰难梭菌感染，技术战略委员会已提供赠款资金以完成人体安全性研究。这种药物，以及可能来自同一平台的其他药物，显示出进一步开发治疗其他感染的希望，包括MRSA和其他严重威胁生命的感染，现有药物由于耐药细菌的增加而变得不那么有效。

MGB Biopharma is developing a new class of antibiotic originally discovered in the UK by researchers at the University of Strathclyde. The drug,MGB-BP-3, has a novel mechanism of action which means that resistant bacteria will not be a feature as is the case with existing antibiotics. The first indication to be developed is the treatment of Clostridium difficile infections and the Techology Strategy Board has provided grant funding to complete the human safety study. This drug, and potentially others from the same platform, shows promise for further development for the treatment of other infections, including MRSA and other serious life threatening infections against which existing drugs are becoming less effective due to the increase in resistant bacteria.